

Date: 14th February, 2026

To, National Stock Exchange of India Limited Exchange Plaza, C-1 Block G, Bandra Kurla Complex Bandra [E], Mumbai – 400051 NSE Scrip Symbol: KRONOX	To, BSE Limited 25 th Floor, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001 BSE Scrip Code: 544187
--	--

Subject: Outcome of Board Meeting held on Saturday, 14th February, 2026.

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that, Board of Directors at their meeting held today i.e. on **Saturday, 14th February, 2026** have considered, approved and took on record the followings:

1. Statement of Standalone Unaudited Financial Results for the quarter and Nine Months ended on 31st December, 2025
2. Independent Auditors' Limited Review Report on Financial Results.

The Meeting of Board of Directors commenced at 2:00 p.m. and concluded at 2.30 p.m.

Kindly take the aforesaid information on your record and oblige.

Thanking you

For **KRONOX Lab Sciences Limited**



Nikhil Goswami
Company Secretary & Compliance Officer
Membership No. A68272



KRONOX LAB SCIENCES LIMITED

Corporate Office Address : Block No. 284, Village : Dabhasa, Taluka : Padra, Dist. : Vadodara, Gujarat State - 391 440.
Registered Office Address : Block No. 353, Village : Ekalbara, Taluka : Padra, Dist. : Vadodara, Gujarat State - 391 440.
Phone No. : +91 2662 244077, 244088
Email : info@kronoxlabsciences.com,
CIN : U24117GJ2008PLC055460
Webside : www.kronoxlabsciences.com

KRONOX LAB SCIENCES LIMITED

Regd. Office: Block No. 353, Village: Ekalbara, Taluka: Padra, District: Vadodara 391440 Gujarat

email: cs@kronoxlabsciences.com ; CIN: L24117GJ2008PLC055460

Quarterly & Nine Months ended Financial Result by Companies Other than Banks

Unaudited Financial Results for the Quarter and Nine Months ended 31.12.2025

(Rs In Lakhs)

Sr. No	Particulars	Quarter Ended			Nine Months ended		Year Ended
		31.12.2025	31.12.2024	30.09.2025	31.12.2025	31.12.2024	31.03.2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	INCOME FROM OPERATION						
1	Revenue from Operation	2,527.40	2,401.11	2,553.32	7,509.37	7,406.28	10,019.39
2	Other Income	113.25	81.90	104.21	304.78	161.18	252.60
3	Total Income	2,640.65	2,483.01	2,657.53	7,814.14	7,567.46	10,271.99
	EXPENSES						
a	Cost of Materials Consumed	1,270.88	1,254.14	1,021.42	3,579.53	3,570.87	4,867.00
b	Changes in Inventories of Finished Goods, Work in progress and Stock-In-Trade	(84.29)	(66.31)	114.97	(92.40)	83.80	225.33
c	Employee Benefits expenses	213.88	117.72	184.01	576.29	351.20	475.36
d	Finance Costs	3.88	-	3.92	7.80	-	-
e	Depreciation and amortisation Expenses	51.99	35.72	46.84	138.89	103.12	138.20
f	Other Expenses	324.51	259.08	368.37	970.80	862.72	1,139.02
	TOTAL EXPENSES	1,780.85	1,600.35	1,739.53	5,180.90	4,971.71	6,844.91
5	Profit before Tax	859.80	882.66	918.00	2,633.24	2,595.75	3,427.08
6	Tax Expenses						
a	Current Tax	206.91	228.97	250.00	675.51	671.16	886.41
b	Deferred Tax	(6.01)	0.83	0.37	(8.06)	9.40	(7.95)
c	Tax Expenses/Refunds relating to prior years	-	-	-	-	-	1.91
7	Profit after Tax for the Period	658.90	652.86	667.63	1,965.79	1,915.19	2,546.71
8	Other Comprehensive Income						
a	Item that will not be reclassified to profit or loss	-	-	-	-	-	-
(i)	Defined benefit Plan liability/assets	7.09	6.34	7.94	18.28	17.29	24.91
(ii)	Tax Impact on above item	(1.78)	(1.59)	(2.00)	(4.60)	(4.35)	(6.27)
b	Item that will be reclassified to profit or loss	-	-	-	-	-	-
(i)	Exchange difference arising on translation of foreign operations	-	-	-	-	-	-
c	Exceptional Items	-	-	-	-	-	-
9	Total Comprehensive Income for the period	664.21	657.61	673.57	1,979.47	1,928.13	2,565.35
10	Paid up share capital(FV Rs.10/- per share.)	3710.4	3710.4	3710.4	3710.4	3710.4	3710.4
	Other Equity	-	-	-	-	-	5,300.10
11	Earning per equity share (In Rupees) (F V Rs.10/- per share) (Basic & Dilluted)	1.79	1.77	1.82	5.33	5.20	6.91

Notes:

- 1 The above Unaudited results have been prepared in accordance with Indian Accounting Standard (IND AS) notified under section 133 of the companies Act, 2013, read together with relevant rules issued there under and other accounting principles generally accepted in India.
- 2 The above results, have been reviewed by the Statutory Auditors, recommended by the Audit Committee and Approved by the Board of Directors in their meeting held on 14th February, 2026
- 3 The Company is having only one reportable segment under Ind As-108 on "Operating Segments" i.e. manufacturing of High Purity Speciality Fine chemical.
- 4 The previous quarters'/years' figures have been regrouped/rearranged wherever necessary to make it comparable with the current quarter/year.

Date: 14/02/2026
Place: Vadodara

For and on behalf of the Board of
KRONOX LAB SCIENCES LIMITED

Ketan Ramani
Whole Time Director
DIN:01510833





Independent Auditor's Review Report on the Unaudited Standalone Financial Results of KRONOX LAB SCIENCES LIMITED for quarter and nine months ended December 31, 2025 Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Review report to
The Board of Directors
KRONOX LAB SCIENCES LIMITED

We have reviewed the accompanying statement of unaudited financial results of **KRONOX LAB SCIENCES LIMITED** (the "Company") for the quarter and nine months ended 31st December 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

The Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Mahesh Udhvani & Associates

Chartered Accountants

FRN :129738W

M. A. Udhvani



Mahesh Udhvani

Partner

M.N:- 047328

UDIN: 26047328WAFBZF5380

Place: Vadodara

Date: 14/02/2026